In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Find out which weight loss injections work best, how fast you can expect results, and whether combining them with other ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Drugs such as Wegovy, Ozempic, and Saxenda have quickly become household names. But are these weight loss medications right ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

As mentioned above, there’s currently a shortage of GLP-1 injections. Compounding pharmacies can create compounded versions to meet the demand. If a healthcare provider recommends you try ...